CDC considers narrowing its Covid-19 vaccine recommendations
The US Centers and Disease Control and Prevention is considering recommending annual Covid-19 shots to those who are older or who have compromised immune function, rather than the current blanket recommendation for everyone 6 months of age and older.
The change would more closely align the US with guidance given in other countries. Unlike countries such as the United Kingdom, Canada and Australia, the US alone recommends an annual Covid-19 vaccine for healthy younger adults and children. The World Health Organization also doesn't routinely recommend annual Covid-19 vaccines for healthy adults under 65 or healthy children.
On Monday, a panel of independent experts that advises the CDC on its vaccine recommendations, called the Advisory Committee on Immunization Practices, weighed the pros and cons of moving the US away from a blanket recommendation that most people get an updated Covid-19 shot every year and toward a more nuanced, risk-based recommendation.
Members of the Covid-19 vaccine work group said they began studying the policy change in November.
Under a risk-based recommendation, the CDC would continue to recommend two doses of Covid-19 vaccines each year for older adults — those over 65 — and to anyone with weakened immune function.
It may also consider recommending annual vaccination for adults and children who are at high risk of Covid-19 disease because they have a higher risk of being exposed to it. Those groups could include people like health-care workers or children in day care.
There was also strong support for a statement in the recommendation to say that anyone who wanted to get a Covid-19 vaccine could still get one, even if they didn't fit into a higher-risk category.
A risk-based recommendation would be more complicated to communicate to the public and potentially trickier to implement than a universal recommendation, and some members of the full committee said they'd be against it for that reason.
'I guess I'm surprised that we're considering a risk-based recommendation, which in general, we have not had a lot of success with implementing in the US,' said committee member Dr. Denise Jamieson, dean of the Carver College of Medicine at the University of Iowa.
Jamieson said she also worried that some people could lose insurance coverage for their Covid-19 vaccines if the recommendation was softened for some groups.
It's also not clear where the committee might land on underlying health conditions and who would be considered at higher risk based on a pre-existing condition, such as diabetes or heart or lung diseases.
An analysis of data based on the CDC's list of conditions that increase the risk for severe disease from a Covid-19 infection found that 74% of adults have at least one health condition that puts them at risk.
And even though Covid is no longer causing the same kind of punishing waves of illness and death as it once did, it was still the 10th leading cause of death among adults in 2023. From September 2023 through August 2024, it caused roughly 40,000 deaths in the US.
'Covid is still a fairly dangerous disease and very, very common,' said committee member Dr. Jamie Loehr, who runs a family practice clinic in Ithaca, New York.
Loehr said he wondered how feasible it might be to implement a risk-based recommendation and what message it might send to the public.
'Even though I'm in favor of a risk-based recommendation, I still have my hesitations,' he said.
Others worried that exempting healthy adults might make long Covid more common. Studies have shown that vaccination cuts the risk of developing the condition, which affected more than 9 million adults and children in 2023, according to national surveys.
'What I would like to see is modeling around long Covid,' said committee member Dr. Oliver Brooks, the chief medical officer of Watts Healthcare Corp. in Los Angeles. 'My primary concern through all of this at this point is long Covid.'
Though there was concern that risk-based recommendations would decrease vaccination, others pointed out there's no proof that's true.
'There's not clear evidence at all that risk-based approaches are less effective,' said committee member Dr. Noel Brewer, a professor of public health at the University of North Carolina. 'The data supporting that claim are not really there.'
On the whole, members of the committee who have studied the question most closely said they favored switching to risk-based recommendations.
As of April, more than three-quarters of the working group on the Covid-19 vaccine recommendations for this coming fall and winter favored risk-based recommendations, though they don't plan to formally vote on the policy change until the next meeting, which is scheduled for June.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
CDC backtracks on layoffs, rehires more than 400 people
The Centers for Disease Control and Prevention is reinstating more than 400 people who had received layoff notices, according to an email from CDC leadership to employees seen by POLITICO. The rehiring, announced internally today, marks the largest number of employees that the agency has asked back to date. Around half of those employees are in the National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention, and around a third are in the National Center for Environmental Health. Other divisions seeing reinstatements include the National Center for Health Statistics, Center for Forecasting and Outbreak Analytics, Office of Human Resources, Global Health Center, Office of Acquisition Services and Office of Communications. HHS spokesperson Andrew Nixon did not immediately respond to a request for comment. He told Fox News, which first reported the news: 'The Trump Administration is committed to protecting essential services — whether it's supporting coal miners and firefighters through [the National Institute for Occupational Safety and Health], safeguarding public health through lead prevention, or researching and tracking the most prevalent communicable diseases.' — Key context: In April, roughly 2,400 CDC employees received termination notices amid a massive reorganization of the Department of Health and Human Services. But the agency has periodically rehired staff over the past few months.
Yahoo
39 minutes ago
- Yahoo
History Shows the Danger of Trump's Health Policies
U.S. President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr. attend an event in the East Room of the White House on May 22, 2025 in Washington, DC. Credit - Chip Somodevilla—Getty Images On May 11, 2023, President Joseph Biden ended the COVID-19 public health emergency, calling an finish to the pandemic. By the end of 2023, COVID-19 claimed the lives of over 20 million people around the world. But through international cooperation and evidence-based science, vaccines were developed and the world moved on. Indeed, perhaps the biggest success of the period was the quick production of a COVID-19 vaccine. The research behind the mRNA vaccine had been ongoing since the 1970s, but the emergency of the pandemic and international sharing of knowledge helped bring the vaccine to fruition. Today, the COVID-19 vaccine has been credited with saving 2.4 million lives around the world. But now, the U.S. is choosing competition over cooperation. With President Donald Trump's day one executive order to leave the World Health Organization (WHO)—blaming their COVID-19 response—and the shuttering of USAID, the country is taking steps towards further dividing health efforts across the globe. Here in the U.S., a sudden end to $11.4 billion of covid-related grants is stifling national pandemic preparedness efforts on the local and state levels. And most recently, Health and Human Services Secretary RFK Jr. purged experts from the CDC Advisory Committee, putting lives at risk. Historical lessons demonstrate the need for global health infrastructure that works together, shares knowledge, and remembers that pathogens do not stop at borders. White House's Pandemic Office, Busy With Bird Flu, May Shrink Under Trump One of the greatest global health achievements of all time—smallpox eradication—provides a perfect example of what can be done with independent scientific research and international cooperation. During the Cold War between the U.S. and USSR, decades of tension brought the world to the brink of nuclear war. Yet, incredibly, the nations managed to find common ground to support the efforts of smallpox eradication. Indeed, they understood the strategic benefits that came from letting public health practitioners and scientists work outside of political divides. The WHO was founded after World War II in 1948. Its formation marked a move from international health, that focused on nations, to global health, that would serve humanity first. The WHO's first eradication effort was the failed, U.S.-backed, Malaria Eradication Program from 1955 to 1969. The Smallpox Eradication Program, with intensive efforts beginning in 1967, provided a chance for redemption for the U.S. and WHO. For the United States, investing in disease eradication and poverty helped to mitigate growing backlash against the Vietnam War. In June of 1964, President Lyndon B. Johnson stated, 'I propose to dedicate this year to finding new techniques for making man's knowledge serve man's welfare.' He called for 1965—the same year he ordered ground troops to Vietnam to stop the spread of communism —to be a year of international cooperation that could bypass the politics of the Cold War. Previously, the USSR did not participate in the U.S. and WHO's first, failed global eradication plan for malaria. But upon rejoining the WHO in 1956, it was the Soviets who made the first call and investment into global eradication of smallpox in 1958. The WHO functioning as a mediator was crucial to allowing the USSR and the U.S. to work together. It allowed both nations to avoid giving credit to each other; rather success went to science itself. President Johnson called this 'a turning point' away from 'man against man' towards 'man against nature.' The limited role of politicians in the program proved to be key to its success. Scientists made decisions and worked together—no matter what country they came from—by focusing on disease and vaccination, not international tensions. The Soviet-initiated program was lead by Donald A. Henderson, a U.S. epidemiologist, who worked alongside the Russians until the last case of smallpox occurred in Somalia on October 26, 1977. During the 20th century, smallpox was responsible for an estimated 300 to 500 million deaths. Smallpox was officially declared eradicated by the WHO in October 1980, and is today still the only human disease to achieve this distinction. Less than a year after the declaration of smallpox eradication, the emergence of another pandemic, the HIV/AIDS crisis, reinforced the importance of science-first cooperation over politically-driven decision making. In June 1981, the first cases of a new unknown disease were reported in the CDC's Morbidity and Mortality Weekly Report. In short order, gay men were stigmatized and blamed in what would become one of the biggest public health disasters of all time. It took years of grassroots science-based activism to move beyond HIV/AIDS victim-blaming and find medical solutions. The Poster Child for AIDS Obscured as Much About the Crisis as He Revealed Too often, governments across the globe placed blame on the gay community for their 'sins' and did not provide needed support, leaving the sick to suffer and die. The pharmaceutical companies profited from the limited medications they had available and did not pursue sufficient development. The FDA process for new drugs was scheduled to take nine years, at a time when life expectancy after receiving an HIV/AIDS diagnosis was one year. These issues sparked activism, spawning the AIDS Coalition to Unleash Power (ACT UP) in 1987. ACT UP organizers took science into their own hands and began educating themselves. Members began reading scientific journals religiously, learning the chemistry and epidemiology of drug manufacturing and clinical trials. Members learned how to translate these dense scientific messages to educate the community members on what was—and what was not—being done to help. Because of this work, the FDA changed policies to allow for new treatments to be tested at accelerated rates in times of emergency. ACT UP was able to shift the cultural blame showing that the issue was a result of politics getting in the way of scientific advancements. By 1990, ACT UP influenced the largest federal HIV program to pass Congress, the Ryan White CARE Act. This program was a vital precursor to the 2003 PEPFAR (The U.S. President's Emergency Plan for AIDS Relief) global initiative. Both of these histories offer a powerful lesson: global health is national health, and national health is local health. With the recent funding cuts from the U.S. government, the future of global health is going in an unknown direction. And yet, the occurrence of pandemics is expected to increase in frequency due to climate change, mass migration, urbanization, and ecosystem destruction. It has been estimated that there is about a 25% chance we will have another COVID-sized pandemic within the next 10 years. No matter how secure the world makes borders, history shows that it can not protect us from disease if we do not have a strong, interconnected public health infrastructure. Luke Jorgensen is a Master of Public Health student at Purdue University where his epidemiology research examines human migration and infectious disease. Made by History takes readers beyond the headlines with articles written and edited by professional historians. Learn more about Made by History at TIME here. Opinions expressed do not necessarily reflect the views of TIME editors. Write to Made by History at madebyhistory@
The Hill
an hour ago
- The Hill
What to know about the new ‘Nimbus' COVID variant
The World Health Organization is keeping an eye on a new COVID-19 variant called NB.1.8.1, or 'Nimbus,' that has spread across Europe, the Americas and the Western Pacific. Nimbus is a descendant of the Omicron variant of the virus and was first identified in late January. Its spike mutations appear to make it more transmissible than other COVID variants, according to the WHO. Spike mutations refer to changes in spike proteins, which sit on the surface of the virus and help it enter healthy cells. While it is spreading in the U.S. and Canada, along with 20 other countries, it does not appear to be driving an increase in sickness or hospitalization. In April, NB.1.8.1 sequences made up 10.7 percent of all submitted sequences from confirmed COVID infections, up from 2.5 percent a month earlier, according to a risk evaluation released by the WHO. The WHO last month deemed NB.1.8.1 a variant 'under monitoring.' Here's what to know about the variant. Most cases of COVID-19 in the U.S. still stem from the LP.8.1 strain, another Omicron descendant. But it looks like NB.1.8.1 might soon replace it as the more common strain, according to data from the Centers for Disease Control and Prevention (CDC). The CDC estimates that 37 percent of COVID-19 cases in the U.S. stem from the NB.1.8.1 variant while 38 percent are a result from an infection of the LP.8.1 strain of the disease. At the end of May, the agency estimated that the NB.1.8.1 variant caused about 15 percent of all COVID cases. But the agency notes on its website that due to low numbers of virus sequences being reported, precision in the most recent reporting period is low. The NB.1.8.1 variant has been found in at least 13 states, according to Today, which cited data from the Global Initiative on Sharing All Influenza Data (GISAID) database. Those states are: California, New York, New Jersey, Maryland, Arizona, Illinois, Hawaii, Massachusetts, Ohio, Rhode Island, Vermont, Virginia and Washington. The available data on 'Nimbus' suggests that it poses a low global threat and that existing COVID-19 vaccines provide adequate protection against severe illness and hospitalization, according to the WHO. 'Currently approved COVID-19 vaccines are expected to remain effective to this variant against symptomatic and severe disease,' reads the WHO's risk evaluation. 'Despite a concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation.' Lionel Gesh, an international consultant at the WHO, told The Hill that many new cases in Canada are likely linked to the NB.1.8.1 variant, but that there has not been any major changes in the country in terms of cases, hospitalizations, ICU admissions or deaths linked to COVID-19. Symptoms of NB.1.8.1 seem to be similar to those associated with other Omicron variants, according to Gresh. Some common COVID-19 symptoms include cough, fever, fatigue, muscle aches, congestion, headache, nausea, vomiting, and a new loss of smell or taste, according to the CDC. 'We should be as concerned about [NB.1.8.1] as we are concerned for COVID in general,' Gesh said. 'Not more, not less.' Some recent COVID-19 patients have reported experiencing something called 'razor blade throat,' according to Salon. But it is unclear if that symptom is connected to one of the COVID variants or another respiratory illness circulating, Ryan Gregory, an evolutionary and genome biologist at the University of Guelph in Canada, told the outlet.
